Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

What Happened? A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as ...

There was also a positive sign for investors worried about the rapid pace at which the company has been burning through its ...

Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on core ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (NASDAQ: MRNA). Biotech stocks generally rise after a product they spent years developing earns ...

Officials with Massachusetts biotechnology company Moderna said Wednesday that an updated version of the company's COVID-19 booster shot appears to be effective against a pair of omicron subvariants ...